No quarterly revenue total was found in ADIAL PHARMACEUTICALS, INC.'s SEC filings.
Adial Pharmaceuticals, Inc. (AZR) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-51.99M
-2555.2% vs year-ago quarter
Operating cash flow
$-6.36M
-263.7% vs year-ago quarter
Free cash flow
—
EPS
$-11.25
-144.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
2.63M
-88.0% vs year-ago quarter
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AZR (Nasdaq), ADIL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Encino, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1513525
- Former names
- ADIAL PHARMACEUTICALS, INC. (until Oct 30, 2026); Adial Pharmaceuticals, L.L.C. (until Sep 28, 2017); ADial Pharmaceuticals, L.L.C. (until Sep 28, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$52.0M | -$2.0M | -$1.9M | -$1.8M | -$1.9M |
| Net income | -$52.0M | -$2.0M | -$2.0M | -$1.8M | -$2.0M |
| Diluted EPS | -$11.25 | -$1.48 | $0.05 | -$0.08 | -$4.61 |
| Operating cash flow | -$6.4M | -$1.6M | -$1.3M | -$1.8M | -$1.7M |
| Total assets | $29.1M | $5.2M | $6.7M | $5.7M | $6.8M |
| Total liabilities | $28.9M | $1.5M | $1.4M | $1.2M | $1.2M |
| Stockholders' equity | -$38.4M | $3.7M | $5.3M | $4.5M | $5.6M |
| Cash and investments | $28.7M | $4.6M | $5.9M | $4.6M | $5.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change, Shareholder vote results, Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 10-Q/A | Amended quarterly report | Oct 21, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 16, 2026 | Oct 15, 2026 |
| 8-K |
Current report
Other events
|
Oct 2, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 18, 2026 | Sep 17, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 16, 2026 | Sep 16, 2026 |
All 575 Adial Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.